Clinical Research in ALS Study (CRiALS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00136500|
Recruitment Status : Recruiting
First Posted : August 29, 2005
Last Update Posted : April 13, 2022
|Condition or disease|
|Amyotrophic Lateral Sclerosis|
|Study Type :||Observational|
|Estimated Enrollment :||10000 participants|
|Official Title:||Clinical Research in Amyotrophic Lateral Sclerosis|
|Study Start Date :||February 2005|
|Estimated Primary Completion Date :||December 2027|
|Estimated Study Completion Date :||December 2027|
Individuals affected with ALS
This population be sporadic or familial ALS.
Unaffected individuals from families in which the genetic cause of ALS is known
This population includes pre-symptomatic individuals at genetic risk for ALS or a related neurodegenerative disorder (i.e., FTD).
Individuals affected with an ALS-related neurodegenerative disease
This would include FTD, MSP, IBMPFD, etc.
- Recruitment [ Time Frame: Annually ]Since this is an umbrella/gateway protocol through which individuals are recruited to participate in a range of studies, outcome is assessed in terms of recruitment.
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00136500
|Contact: Anne-Laure Grignon, MDfirstname.lastname@example.org|
|United States, Florida|
|University of Miami||Recruiting|
|Miami, Florida, United States, 33136|
|Contact: Anne-Laure Grignon, MD 888-413-9315 email@example.com|
|Principal Investigator:||Michael Benatar, MD, PhD.||University of Miami|